Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Kilitch Drugs(I) Ltd.
Swot
Kilitch Drugs(I) Ltd. SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Kilitch Drugs(I) Ltd. has 30 Strengths, 3 Weaknesses, 1 Opportunities and 0 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(30)
Weakness
(3)
Opportunity
(1)
Threats
(0)
Others
(2)
High DVM Mid and Small Caps (subscription)
Growth Factor Screener: Rising returns on equity (ROE), Momentum, and Earnings Yield
Benjamin Graham Value Screen
Strong Performer, Getting Expensive (DVM)
Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE
Companies with 10% increase in share price over three months, with rising net profit growth
Strong Momentum: Price above short, medium and long term moving averages
Consistent Highest Return Stocks over Five Years
Stocks with Consistent Share Price Growth (subscription)
Relative Outperformance versus Industry over 1 Month
Companies with high TTM EPS Growth
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Effectively using its capital to generate profit - RoCE improving in last 2 years
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Net Profit with increasing Profit Margin (QoQ)
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Increasing Revenue every quarter for the past 3 quarters
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Near 52 Week High
RSI indicating price strength
Stocks Outperforming their Industry Price Change in the Quarter
Companies with growing costs YoY for long term projects
Declining Net Cash Flow : Companies not able to generate net cash
Top Losers
Weekly Momentum Gainers
Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
